Senzime is a leading global medical device company, developing precision-based patient monitoring solutions that drive a global paradigm shift in perioperative patient safety. Our cutting-edge solutions TetraGraph and ExSpiron 2Xi are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory functions during and after surgery. With our dedicated team and strong partnerships, we are on a global mission to safeguard every patient's journey, from anesthesia to recovery. Established in 1999, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). #senzime #tetragraph #patientsafety #tofmonitoring #anesthesia
$309K sweet spot round size
1999
$309K
from investors over 1 rounds
Senzime raised $309K on May 11, 2017